News Novartis and Pear to develop substance use digital therapeut... Novartis is set to develop and commercialise a range of digital therapeutics for patients with substance and opioid use disorders as it expands its work with Pear Therapeutics through a dea
Partner Content Partner Content Explore innovative approaches and novel targets in analgesic... The opioid crisis has cost the economy $1 trillion since 2001 in the USA alone, and the prospect does not look like it will get better any time soon.
News Troubled Mallinckrodt pays $1.2bn for Sucampo Specialist pharma company Mallinckrodt announced on 26 December that it is to acquire Sucampo Pharmaceuticals for around $1.2 billion.
News FDA encourages cheap abuse-deterrent painkillers Regulator waiting for non-opioid alternatives to reach the market
News Sanofi's Dupixent scores double COPD win in US, China Originally anticipated in June, the FDA action stands to make Sanofi and Regeneron's biologic blockbuster even bigger.
Sales & Marketing Sponsored Shifting the paradigm in pharma marketing with content trans... Content transformation is changing pharmaceutical marketing. Join us to learn new strategies and approaches for this new world of patient centricity.